γ-Hydroxybutyrate Orphan Medical

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 278-283

  Tunnicliff, Godfrey ^a   Raess, Beat U ^a  

^a Indiana University School of Medicine Evansville   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; METHYLPHENIDATE; MODAFINIL; NCS 382; OXYBATE SODIUM; PHYSOSTIGMINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; CATAPLEXY; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ABUSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG FATALITY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; HYPNOSIS; LD 50; NARCOLEPSY; NONHUMAN; RESPIRATORY FUNCTION DISORDER; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VERTIGO;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUGS, INVESTIGATIONAL; GABA AGONISTS; HUMANS; NARCOLEPSY; RECEPTORS, GABA-B; SODIUM OXYBATE; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0036232131     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. γ-Hydroxybutyrate and narcolepsy: A double-blind placebo-controlled study
2. Orphan Medical (company prospectus)
3. Orphan Medical announces Xyrem clinical trial results
4. Approval of HR 2130 by the House of Representatives will allow for the continued research of Xyrem (sodium oxybate) oral solution for the treatment of narcolepsy
5. Orphan Medical reports positive clinical trial results for Xyrem®, potential treatment for narcolepsy
6. Congressional bill supporting the continued development of medically formulated GHB moves to the President
7. President Clinton signs HR 2130 protecting the medical use of GHB; Scheduling of Orphan Medical's Xyrem defined
8. Xyrem NDA for narcolepsy symptoms submitted by Orphan Medical
9. Orphan Medical presents positive trial results at JP Morgan H&Q Healthcare Conference; Preliminary revenues for fiscal year 2000 exceed $11.0 million
10. Orphan Medical announces new date for FDA Advisory Committee meeting for Xyrem (sodium oxybate) oral solution NDA
11. Xyrem (sodium oxybate): Pharmacokinetic interactions with PROVIGIL (Modafinil) in healthy human subjects
12. Additional clinical data for Orphan Medical's Xyrem demonstrate overall improvement for narcolepsy patients - Data released at Annual Meeting of Orphan Shareholders
13. Orphan Medical Xyrem FDA study request could delay launch until mid-2002
14. Orphan Medical Reports second quarter results; Provides update on Xyrem (sodium oxybate) oral solution
15. GHB: A new and novel drug of abuse
16. Pharmacokinetics of γ-hydroxybutyrate (GHB) in narcoleptic patients
17. Neurodegeneration, sleep, and cerebral energy metabolism: A testable hypothesis
18. Sanofi-Synthélabo: The top 40 industrial companies
19. B receptors in the hippocampal CA3 region
20. Sodium 4-hydroxybutyrate
21. Significance of γ-hydroxybutyric acid in the brain
22. γ-Hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices
23. B receptors
24. 3H]hydroxybutyrate binding site as determined by quantitative autoradiography
25. B binding sites in rat central nervous system: A quantitative autoradiographic study
26. Conversion in vivo of γ-aminobutyric acid to γ-hydroxybutyric acid in mammalian brain
27. Cloning of a rat brain succinic semialdehyde reductase involved in the synthesis of the neuromodulator γ-hydroxybutyrate
28. Preliminary report on the metabolism of γ-butyrolactone and γ-hydroxybutyric acid
29. A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties
30. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist
31. Effects of fatty acid anions on electroencephalogram of unanesthetized rabbits
32. γ-Hydroxybutyrate, succinic semialdehyde and sleep
33. Slow wave sleep and a state resembling absence epilepsy induced in the rat by γ-hydroxybutyrate
34. Effects of γ-hydroxybutyrate on chick behaviour, electrocortical activity and crossed-extensor reflexes
35. γ-Hydroxybutyric acid is not a GABA-mimetic agent in the spinal cord
36. The action of sodium 4-hydroxybutyrate on spinal reflexes
37. Inhibition of nigral and neocortical cells by gamma-hydroxybutyrate: A microiontophoretic investigation
38. Effect of γ-hydroxybutyrate on the release of monoamines from the rat striatum
39. Dopaminergic neurons: Similar biochemical and histochemical effects of γ-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway
40. Selective increase of brain dopamine induced by γ-hydroxybutyrate
41. Effect of γ-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum
42. γ-Hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices
43. Evidence for a G protein-coupled γ-hydroxybutyric acid receptor
44. High affinity binding site for γ-hydroxybutyric acid in rat brain
45. γ-Hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertussis toxin
46. γ-Hydroxybutyric acid: An endogenous neuromodulator with abuse potential?
47. γ-Hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study
48. γ-Hydroxybutyric acid for treatment of opiate withdrawal syndrome
49. Effect of γ-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report
50. Effects of enhancing slow wave sleep by γ-hydroxybutyrate on obstructive sleep apnea
51. γ-Hydroxybutyric acid
52. Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat
53. γ-Hydroxybutyric acid as hypnotic
54. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness
55. 14C]γ-hydroxybutyric acid by rat brain after intraventricular injection
56. Metabolism of γ-hydroxybutyric acid
57. Sites of action of γ-hydroxybutyrate (GHB) - A neuroactive drug with abuse potential
58. Therapeutic γ-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry
59. γ-Hydroxybutyrate-associated deaths
60. In-patient detoxification after GHB dependence
61. Physical dependence on sodium oxybate
62. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate
63. Physostigmine in the treatment of γ-hydroxybutyric acid overdose
64. Reversal of the anesthetic action of sodium γ-hydroxybutyrate
65. The treatment of narcolepsy-cataplexy with nocturnal γ-hydroxybutyrate
66. Treatment of narcolepsy with γ-hydroxybutyrate. A review of clinical and sleep laboratory findings
67. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy
68. Efficacy of γ-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: Double-blind subjective measures
69. γ-Hydroxybutyrate; A health-food product producing coma and seizurelike activity
70. Über die wechselseitige Umwandlung der Laktone und Oxysaren
71. GHB: The natural mood enhancer
72. Pharmacologie comparée des sels de l'acide butyrique et de l'acide 4-hydroxybutyrique
73. Sodium γ-hydroxybutyric acid: A new anaesthetic adjuvant
74. Various seizure activities following γ-hydroxybutyrate
75. 3H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-yliden e) ethanoic acid in the rat brain
76. B receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid